85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004447-23-DE (EUCTR) | 04/07/2019 | 07/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Netherlands;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2018-004447-23-GB (EUCTR) | 20/05/2019 | 15/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial RESPIVANT RVT1601-cc-04 | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;New Zealand;Italy;United Kingdom | ||
| 3 | EUCTR2018-004447-23-CZ (EUCTR) | 15/05/2019 | 14/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| 4 | EUCTR2018-004447-23-BE (EUCTR) | 02/05/2019 | 01/04/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| 5 | EUCTR2018-004447-23-NL (EUCTR) | 16/04/2019 | 07/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czechia;Czech Republic;Canada;Belgium;Turkey;Australia;Germany;Netherlands;United Kingdom;Italy;New Zealand |